Incyte Corporation (INCY) stock analysis
Healthcare · Biotechnology
From the 10-K filed 2026-02-10
How it makes money
Payors like insurance companies and governments pay for Incyte's medicines to treat rare blood cancers and immune disorders.
Almost all patients require third-party coverage to afford the high costs of these medicines.
Consequently, government programs and private insurers act as the primary payors for these treatments.
What protects it: the moat
Incyte relies on patent protection, but its main drug loses exclusivity in 2028.
The company holds patents that cover the composition and use of ruxolitinib.
These protections are expected to expire in mid and late 2028.
What growth costs
It must invest in research and development to find new drugs and replace lost revenue.
The company devotes substantial resources to discovery, clinical development, and acquiring rights to new product candidates or technologies.
What could damage it
The loss of JAKAFI patent exclusivity in 2028 could cause a significant decline in revenue.
Because JAKAFI is a major revenue contributor, its patent expiration will likely lead to declining sales as competing products enter the market.
About Incyte Corporation
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease. It also provides INCA033989 for the treatment of essential thrombocythemia and MF; INCA035784 for the treatment of anti-mutant calreticulin and myeloproliferative neoplasms (MPNs); INCB160058 for the treatment of MPNs; PEMAZYRE, a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ZYNYZ to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma. The company's clinical stage products include INCB123667 for ovarian cancer; INCB161734 for solid tumors; INCA33890 for cancers; Ruxolitinib cream for atopic dermatitis, hidradenitis suppurativa (HS), and prurigo nodularis; Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma; and INCB00928 for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreement with Novartis, Lilly, and Syndax. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and distributors. Incyte Corporation has a clinical trial collaboration with Genmab A/S to evaluate petosemtamab. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.